Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Core Needle Biopsy), By Application (Breast Cancer, Lung Cancer), By Product (Kits & Consumables, Instruments), By Region, And Segment)- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

Cancer Biopsy Market Size and Trends

The global cancer biopsy market size was estimated at USD 25.35 billion in 2023 and is expected to be worth around USD 134.96 billion by 2033, poised to grow at a compound annual growth rate (CAGR) of 18.2% during the forecast period 2024 to 2033.

Cancer Biopsy Market Key Takeaways

• Tissue biopsy generated the highest revenue and accounted for 63.42% of the total revenue in 2023.
• Liquid biopsies are anticipated to expand at the fastest CAGR over the forecast period.
• Breast biopsy emerged as the dominant segment with a market share of 16.31% in 2023, and the same is anticipated to grow at the fastest CAGR over the forecast period.
• Kits and consumables accounted for a revenue share of 61.45% in 2023.
• Instruments are anticipated to grow at the fastest CAGR over the forecast period.
• North America market generated the highest revenue in 2023 and accounted for 41.85% of the total revenue generated.

Cancer Biopsy Market Growth Factors

The market is projected to experience substantial growth due to several key factors. One of the primary drivers is the increasing prevalence of oncology cases, which is further fueled by the expanding geriatric population. Additionally, the introduction of liquid biopsy and continuous advancements in biopsy techniques are expected to significantly contribute to market expansion.Furthermore, within the field of oncology diagnostics, various biopsy techniques are utilized, including endoscopic, bone marrow, skin, needle, and surgical biopsies.

Among these, needle biopsies have emerged as a preferred method for early detection of patients. Specifically, fine needle aspiration (FNA) type needle biopsies offer notable advantages, such as minimal invasiveness and quicker results, leading to further growth in the market. Additionally, a series of advancements in image-guided biopsies and expanding applications of the same have been marked as a key trend in recent years. For instance, in March 2022 liquid biopsy provided the opportunity to detect cancer in various fluid bodies, and the advanced liquid biopsy enabled an attractive noninvasive procedure to get biomaterials from cancer for diagnosis.

The introduction of liquid biopsy in the fields of cancer diagnosis, screening, prognosis, and treatment monitoring has brought about a substantial increase in competition and advancements within the market. Companies actively involved in entering or conducting liquid biopsies are seen as crucial drivers of growth in clinical settings. For instance, in June 2023, LabCorp introduced a liquid biopsy aimed at identifying cancer-related biomarkers. This innovative blood test has the potential to enable cancer patients to initiate one of the most effective treatments at the earliest possible stage. Presently, liquid biopsy is primarily utilized for patients who are unable to undergo tissue biopsies, especially for the diagnosis of advanced and metastatic cancer cases.

Moreover, in June 2018, Data Driven Diagnostics Sciences, Inc., commonly referred to as D3Sciences (D3S), which is a startup, developed a cutting-edge needle biopsy instrument for minimally invasive procedures. This innovative device incorporates electrosurgery and electrocautery techniques to safely enhance the volume of tissue samples collected. The company's primary goal is to expedite cancer diagnosis and treatment by ensuring the acquisition of optimal tissue samples, enabling more effective personalized medicine approaches. This is anticipated to fuel the growth of the segment over the period.

Cancer Biopsy Market Report Scope

Cancer Biopsy Market Trends

• Technological Advancements: The field of oncology continues to benefit from advancements in technology. This includes improvements in imaging techniques such as MRI, CT scans, and ultrasound, which aid in guiding biopsy procedures and locating tumors with greater precision. Additionally, advancements in molecular diagnostics, such as next-generation sequencing (NGS) and liquid biopsies, are revolutionizing cancer diagnosis and treatment selection.
• Rise of Liquid Biopsies: Liquid biopsies, which involve analyzing biomarkers such as circulating tumor cells (CTCs) or cell-free DNA (cfDNA) from a blood sample, are gaining traction in cancer diagnostics. These minimally invasive tests offer advantages over traditional tissue biopsies, including the ability to detect tumor mutations, monitor treatment response, and identify resistance mechanisms through serial sampling.
• Personalized Medicine: The era of personalized medicine is transforming cancer care. Biopsy samples are increasingly being used to identify specific molecular alterations or biomarkers within tumors, guiding the selection of targeted therapies tailored to individual patients. This approach not only improves treatment efficacy but also minimizes unnecessary exposure to potentially ineffective treatments and associated side effects.
• Immunotherapy Integration: Immunotherapy has emerged as a groundbreaking treatment modality for various cancers. Biopsies play a crucial role in assessing biomarkers such as programmed death-ligand 1 (PD-L1) expression or tumor mutational burden (TMB) to predict response to immunotherapy. As immunotherapy continues to expand across different cancer types, the demand for biomarker testing through biopsies is expected to grow.
• Integration of Artificial Intelligence (AI): AI and machine learning algorithms are being integrated into various aspects of cancer biopsy analysis. These technologies aid in image interpretation, tumor classification, and prediction of patient outcomes based on biopsy data. AI-powered tools have the potential to enhance the accuracy and efficiency of biopsy procedures, ultimately improving patient care and treatment outcomes.
• Shift towards Minimally Invasive Techniques: There is a growing preference for minimally invasive biopsy techniques, such as needle biopsies (e.g., core needle biopsy, fine-needle aspiration) and endoscopic biopsies, over surgical procedures. Minimally invasive techniques offer advantages such as reduced patient discomfort, shorter recovery times, and lower healthcare costs. They also allow for repeated sampling of tumors, facilitating longitudinal monitoring of disease progression and treatment response.
• Global Increase in Cancer Incidence: The global burden of cancer continues to rise due to factors such as aging populations, lifestyle changes, and environmental exposures. As the prevalence of cancer increases, so does the demand for cancer diagnostic procedures, including biopsies. This trend is driving market growth for biopsy services and related diagnostics worldwide.
• Telemedicine and Remote Consultations: The COVID-19 pandemic has accelerated the adoption of telemedicine and remote consultations in healthcare, including cancer care. Remote biopsy consultations enable multidisciplinary collaboration and facilitate access to expert opinions, particularly in regions with limited healthcare resources or during times of crisis.

Type Insights

Tissue biopsy generated the highest revenue and accounted for 63.42% of the total revenue in 2023. It is still considered to be a mainstay of biopsies and is largely adopted across various cancer diagnosis applications. This is attributed to robust research activities evaluating its safety and efficacy, which have contributed to this segment’s dominance in the global market throughout the forecast period.

Advancements targeted towards enhancing tissue biopsy procedures are expected to maintain its dominance in the global market for the next few years. For instance, Cernostics is developing an assay suitable for diagnosing cancer patients suffering from Barrett's Esophagus. This one-of-a-kind diagnostic test makes use of biopsy images that are digitally scanned, which aids in the analysis and quantification of alterations occurring at cellular or molecular levels within a tissue.

Liquid biopsies are anticipated to expand at the fastest CAGR over the forecast period. A rising preference toward liquid biopsy among physicians has been observed in recent years, supplemented by its ability to offer disease snapshots from the primary and distant tumor sites. This approach is put to use in personalized medicine treatment wherein tumor markers are sampled repeatedly to alter the therapy based on the patient’s response to the treatment. Furthermore, the companies are combining liquid biopsy along with advanced AI technology for better analysis of mutations in DNA. For instance, GC Genome Corporation, a South Korean based-company, in April 2023, announced its collaboration with the Korea Advanced Institute of Science and Technology (KAIST), thus highlighting the company’s new AI-based liquid biopsy technology for better DNA mutation analysis.

Application Insights

Breast biopsy emerged as the dominant segment with a market share of 16.31% in 2023, and the same is anticipated to grow at the fastest CAGR over the forecast period. Breast cancer has the highest prevalence rate. Around 1 in 8 U.S. women develop invasive breast cancer as per the U.S. breast cancer statistics. For instance, in 2022,In the US, women will be diagnosed with 287,850 new cases of invasive breast cancer, 51,400 cases of DCIS, and 43,250 will pass away from breast cancer.

Rising number of patients suspected of having breast cancer are subjected to microscopic analysis of breast tissue which is mandatory to obtain a definitive diagnosis along with detecting the stage and characterization of type. This has propelled the demand for a needle biopsy or surgical biopsy to obtain tissue for microscopic analysis, in turn contributing to the segment dominance.

Circulating tumor cells (CTC)-based liquid biopsies can track the minimal residual disease (MRD) in nonmetastatic prostate cancer patients along with the follow-up evaluations performed to offer independent prognostic insights. A novel European project initiated, Transcan—PROLIPSY is designed to assess the potential of combined use of CTCs, exosomes, and ctDNA as a noninvasive liquid biopsy modality to diagnose prostate cancer followed by its routine evaluation.

Product Insights

Kits and consumables accounted for a revenue share of 61.45% in 2023 as these are integral across various stages of biopsies and robust investments by key players operating in this industry have made significant contributions. This is also supplemented by a considerable increase in the number of patients across the globe who demand instruments and kits to be efficient accurate, and rapid. Cancer biopsy has witnessed several developments in terms of instruments, kits, and consumables. For instance, in December 2022, Summit Medical LLC. announced the launch of a single-use instrument to its product line for cervical rotating biopsy punch, which supports immediately required processes such as cancer diagnosis.

Instruments are anticipated to grow at the fastest CAGR over the forecast period. Several developing manufacturers are concentrating on launching instruments that can enhance endoscopy-based biopsies. For instance, in May 2022, Limaca Medical, an Israel-based company, announced the launch of Precision-GI, which is designed to provide a conclusive diagnosis through histologic and genetic testing of endoscopic biopsy tissues.

Regional Insights

North America market generated the highest revenue in 2023 and accounted for 41.85% of the total revenue generated. North America is anticipated to maintain a dominant share throughout the forecast, with the U.S. making significant contributions to the regional revenue. In addition, distributors and manufacturers operating in this region aim to distribute as well as develop novel kits that are well-suited for rapid diagnostic applications.

Moreover, the increasing adoption of liquid biopsies across the U.S. is largely favored by the profitable strategies laid out by the respective government authorities. Regulatory strategies for liquid biopsy-based oncology diagnostics rely on the framework, which has been developed in recent years by the US Food and Drug Administration (FDA).

This framework is comprised of the guidelines associated with enrichment biomarkers as well as companion diagnostics, and approval precedents. The ultimate success of liquid biopsy regulatory pathways has been supplemented by the increased value of Clinical Laboratory Improvement Amendment (CLIA) ‐developed tests, which the FDA has approved.

Cancer Biopsy Market Top Key Companies:

• Qiagen N.V.
• Illumina, Inc.
• ANGLE Plc
• BD (Becton, Dickinson and Company)
• Myriad Genetics
• Hologic, Inc.
• Biocept, Inc.
• Thermo Fisher Scientific, Inc.
• Danaher
• F. Hoffmann-La Roche Ltd.
• Lucence Diagnostics Pte. Ltd.
• GRAIL, Inc.
• Guardant Health
• Exact Sciences Corporation
• Freenome Holdings, Inc.
• Biodesix (Integrated Diagnostics)
• Oncimmune
• Epigenomics AG
• HelioHealth (Laboratory for Advanced Medicine)
• Genesystems, Inc. (Genesys Biolabs)
• Chronix Biomedical, Inc.
• Personal Genome Diagnostics Inc.
• Natera, Inc.
• Personalis Inc.

Cancer Biopsy Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Cancer Biopsy market.

By Product 

• Instruments
• Kits And Consumables
• Services

By Type 

• Tissue Biopsies
  • Needle Biopsies
    • Fine Needle Aspiration (FNA)
    • Core Needle Biopsy (CNB)
  • Surgical Biopsies
• Liquid Biopsies
• Others

By Application 

• Breast Cancer
• Colorectal Cancer
• Cervical Cancers
• Lung Cancers
• Prostate Cancers
• Skin Cancers
• Blood Cancers
• Kidney Cancers
• Liver Cancers
• Pancreatic Cancers
• Ovarian Cancers
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)